Assess feasibility and safety of the Prostatic Urethra Lift (PUL) procedure in patients with acute urinary retention secondary to benign prostatic hyperplasia (BPH).

The study is a multi-centre, prospective evaluation of PUL and retrospective review of invasive surgery as potential comparator. The study is intended to be conducted at up to 5 different centres in the United Kingdom to enrol up to 50 subjects. Subject follow-up visits are at post-procedure, 6 weeks, 3 months, 6 months and 12 months.

UroLift System Procedure Arm

Inclusion Criteria:

1. Male gender
2. Diagnosis of symptomatic BPH
3. Age ≥ 50 years
4. Prostate volume ≤ 100 cc per ultrasound (US)
5. Acute urinary retention with at least one failed trial without catheter (TWOC) while on alpha blocker

Exclusion Criteria:

1. An obstructive or protruding median lobe of the prostate

2. Previous BPH surgical procedure

3. Previous pelvic surgery

4. Urethral conditions that prevents insertion and delivery of device system into bladder

5. Retention volume of >1500 mL

6. Has not had prostate cancer excluded

7. History of prostate or bladder cancer

8. Biopsy of the prostate within the 6 weeks prior to Index Procedure

9. History of neurogenic or atonic bladder

10. Acute or chronic renal failure

11. Known coagulopathies or subject on anticoagulants within 3 days of index procedure (excluding up to 100mg ASA)

12. Known bladder stones within the prior 3 months or treatment within 12 months

13. Prostatitis requiring treatment (antibiotics) within the last year

14. Other co-morbidities that could impact the study results

    • severe cardiac arrhythmias uncontrolled by medications or pacemaker
    • congestive heart failure New York Heart Association (NYHA) III or IV
    • history of uncontrolled diabetes mellitus
    • significant respiratory disease in which hospitalisation may be required
    • known immunosuppression (i.e. AIDS, post-transplant, undergoing chemotherapy)

15. Life expectancy estimated to be less than 5 years

16. Desire to maintain fertility post procedure

17. Unable or unwilling to complete all required questionnaires and follow up assessments

18. Unable or unwilling to sign informed consent form

19. Currently enroled in any other clinical research trial that has not completed the primary endpoint

Index procedure and up to 1 year

An AE is defined as any undesirable medical occurrence in a clinical trial subject, whether it is considered to be related to the device or not, that includes a clinical sign, symptom, or condition An (SAE) is defined as untoward occurrence that:(a) death; (b) life-threatening; (c) requires hospitalisation or prolongation of existing hospitalisation (d) results in persistent or significant disability or incapacity; or (e) is otherwise considered medically significant by the investigator

Data Retrospectively collected from the invasive Benign prostatic hyperplasia (BPH) surgeries (TURP, Holmium Laser Enucleation of the prostate (HoLEP), etc) was not directly comparable to the prospective UroLIFT system outcomes because of inherent standard of care differences between interventions, standard of care at sites and recording in medical records